Fundraising Fox
/Companies
Sign in

Cambridge Cancer Genomics

DefunctYC S17

Cambridge, GB · Founded 2015 · 25 employees · 15 known investors

Find your way into Cambridge Cancer Genomics

Sign up to see every warm intro you have to Cambridge Cancer Genomics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cambridge Cancer Genomics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

CCG.ai develops software that uses clinical and genomic data to help oncologists select appropriate cancer treatments for individual patients, with a focus on identifying predictive biomarkers linked to treatment response.

HealthtechMedical DevicesGenomicsOncologyUnited KingdomEurope

Founders & leadership· Y Combinator alumni (S17)

Cambridge Cancer Genomics was founded in 2015 by John Cassidy, Nirmesh Patel, and Evaline Tsai.

JCJohn Cassidy
John CassidyCEOInvestor at Kindred Capital
NPNirmesh Patel
Nirmesh PatelChief Scientific OfficerNirmesh Patel is founder and Chief Scientific Officer of Cambridge Cancer Genomics, which develops software using clinical and genomic data to help oncologists select cancer treatments tailored to individual patients.
ETEvaline Tsai
Evaline TsaiCPO
JT
Joan TanousOperations Associate
HC
Harry CliffordCTO2017–2021
LH
Luke HarriesMachine Learning Engineer (Contracting and Internship)2018–2018

Investors · 15

FundersClublisted by FundersClubSan Francisco · $290K

How we know: FundersClub's portfolio page · Y Combinator's founder network · Not right? Tell us

Pi Campuslisted by Pi CampusRome · $55K – $540K

How we know: Y Combinator's founder network · Not right? Tell us

Soma Capitallisted by Soma CapitalSacramento · $100K – $300K

How we know: Y Combinator's founder network · somacap.com · Not right? Tell us

Y Combinatorlisted by Y CombinatorSan Francisco · $500K

How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us

AME Cloud VenturesreportedPalo Alto · $1M – $10M

How we know: Y Combinator's founder network · Not right? Tell us

Endure CapitalreportedAmsterdam

How we know: Y Combinator's founder network · Not right? Tell us

FrialereportedNashville · $100K – $600K

How we know: Y Combinator's founder network · Not right? Tell us

Hack VCreportedPalo Alto · $3M

How we know: Y Combinator's founder network · Not right? Tell us

Liquid VenturesreportedSan Francisco · $250K – $5M

How we know: Y Combinator's founder network · Not right? Tell us

MetaplanetreportedTallinn · $500K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

Refactor CapitalreportedBurlingame · $1M – $2M

How we know: Y Combinator's founder network · Not right? Tell us

Romulus CapitalreportedBoston · $250K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

RTLP LLCreportedNew York

How we know: Y Combinator's founder network · Not right? Tell us

Vy CapitalreportedDubai

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 5

GamgeeGAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.
Notable LabsNotable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.
Numerion LabsNumerion combines drug discovery expertise with machine learning and computational chemistry. The company applies AI to drug development.
FidoCureOne Health operates a clinical trial platform using canine cancer data to accelerate and de-risk human oncology drug development. The company leverages a dataset of 2 billion datapoints from dogs with naturally occurring cancer to serve as a comparative model for pharmaceutical R&D, helping drug developers validate efficacy and identify biomarkers before human trials.
Clear GeneClear Gene develops RNA diagnostics for detecting residual solid tumors in cancer patients and provides software and reagent kits to help clinical laboratories process COVID-19 samples more efficiently using existing equipment.

Companies working in the same space as Cambridge Cancer Genomics.

Legal entities · 1

corporate structure
Cambridge Cancer Genomics, Inc.

Frequently asked questions

What does Cambridge Cancer Genomics do?
CCG.ai develops software that uses clinical and genomic data to help oncologists select appropriate cancer treatments for individual patients, with a focus on identifying predictive biomarkers linked to treatment response.
Who founded Cambridge Cancer Genomics?
Cambridge Cancer Genomics was founded by John Cassidy, Nirmesh Patel, Evaline Tsai in 2015.
Who are Cambridge Cancer Genomics's investors?
Cambridge Cancer Genomics's investors include Amplify Partners, FundersClub, Pi Campus, Soma Capital, Y Combinator, AME Cloud Ventures, Endure Capital, Friale and 7 more.
Where is Cambridge Cancer Genomics headquartered?
Cambridge Cancer Genomics is headquartered in Cambridge, GB.